profit from every $100 of sales.
$0$100
Replimune Group
$21.89-0.41% today
+143.8% in 1 year
1-year low $1.701-year high $23.28
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Replimune Group sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$247 million of profit last year.
SalesProfit
Replimune Group vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Replimune Group | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Replimune Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -115 | -174 | -233 | -260 | |
| -114 | -167 | -206 | -235 | |
| -118 | -174 | -216 | -247 | |
| -2.26 | -2.99 | -3.24 | -3.07 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 461 | 647 | 488 | 551 |
| Cash | 106 | 147 | 74 | 111 |
| Total debt | 33 | 61 | 76 | 76 |
| Total liabilities | 50 | 91 | 113 | 135 |
| 411 | 555 | 375 | 416 | |
| 52 | 58 | 67 | 81 | |
| -20.6% | -21.8% | -36.6% | -38.4% | |
| -28.7% | -31.4% | -57.6% | -59.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -82 | -128 | -185 | -192 | |
| 2 | 2 | 6 | 7 | |
| -85 | -130 | -191 | -199 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 24 | 28 | 34 | 35 |
Valuation
- –
- –
- –
- 2.3×
- –
- –
- –
- -9.6%
- -11.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -113.2%
- -33.6%
- -102.7%
- -94.4%
- -115.2%
- –
Growth
- –
- –
- −4.1%
- –
- +14.9%
Financial health
- 0.1×
- 0.36
- 22.9%
- -50.4×
- 5.60
- 5.60
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Bottom 10%of 987
What analysts expect
- Average price target
- $14.00
- Range
- $14.00 – $14.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 3, 2026 | -0.77 | -0.77 | −0.2% |
| Nov 6, 2025 | -0.90 | -0.87 | −3.4% |
| Aug 7, 2025 | -0.95 | -0.83 | −14.5% |
| May 22, 2025 | -0.82 | -0.75 | −9.3% |
| Feb 12, 2025 | -0.79 | -0.70 | −12.9% |
| Nov 12, 2024 | -0.68 | -0.75 | +9.3% |
| Aug 8, 2024 | -0.78 | -0.88 | +11.4% |
| May 16, 2024 | -0.82 | -0.86 | +4.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
46No pass
Philip Fisher
32No pass
Peter Lynch
54No pass
Joel Greenblatt
0No pass
Charlie Munger
26No pass
Terry Smith
25No pass
Questions about Replimune Group
Is Replimune Group a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Replimune Group AI analysis
What does Replimune Group do?
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. It is in Biotechnology.
Does Replimune Group pay a dividend?
No. Replimune Group does not pay a dividend at the moment.
Is Replimune Group stock halal?
Yes. Replimune Group passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has Replimune Group stock done over the past year?
Up 143.8% over the past twelve months, to $21.89. It traded between $1.70 and $23.28 and is 6.0% below its high.
Who are Replimune Group's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Replimune Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.